Brief: Rallybio Announces Positive Preliminary Results For Rlyb212, An Anti-HPA-1A Monoclonal Antibody For The Prevention Of Fetal And Neonatal Alloimmune Thrombocytopenia
28/09/2022 13:13
Sept 28 (Reuters) - Rallybio Corp RLYB.O :
* RALLYBIO ANNOUNCES POSITIVE PRELIMINARY RESULTS FOR
RLYB212, AN
ANTI-HPA-1A MONOCLONAL ANTIBODY FOR THE PREVENTION OF FETAL AND
NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
* PRELIMINARY RESULTS SHOWED ACCEPTABLE SAFETY AND
TOLERABILITY
WITH NO SERIOUS ADVERSE EVENTS.
Source text for Eikon: ID:nBw64jHMFa
Further company coverage: RLYB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx